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ABSTRACT 
Human Langerhans cell (LC) precursors populate the epidermis early during prenatal 
development and thereafter undergo massive proliferation. The prototypic anti-proliferative 
cytokine TGF-β1 is required for LC differentiation from human CD34+ hematopoietic progenitor 
cells and blood monocytes in vitro. Similarly, TGF-β1 deficiency results in LC loss in vivo. 
However, immunohistology studies revealed that human LC niches in early prenatal epidermis 
and adult basal (germinal) keratinocyte layers lack detectable TGF-β1. Here we demonstrated 
that these LC niches express high levels of BMP7 and that Bmp7-deficient mice exhibit 
substantially diminished LC numbers, with the remaining cells appearing less dendritic. BMP7 
induces LC differentiation and proliferation by activating the BMP type-I receptor ALK3 in the 
absence of canonical TGF-β1-ALK5 signaling. Conversely, TGF-β1-induced in vitro LC 
differentiation is mediated via ALK3; however, co-induction of ALK5 diminished TGF-β1-
driven LC generation. Therefore, selective ALK3 signaling by BMP7 promotes high LC yields. 
Within epidermis, BMP7 shows an inverse expression pattern relative to TGF-β1, the latter 
induced in suprabasal layers and upregulated in outer layers. We observed that TGF-β1 inhibits 
microbial activation of BMP7-generated LCs. Therefore, TGF-β1 in suprabasal/outer epidermal 
layers might inhibit LC activation resulting in LC network maintenance.  
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INTRODUCTION 
 
LCs form dense cellular networks in basal/suprabasal layers of stratified epidermal and mucosal 
tissues. LCs are considered as the environmentally exposed outposts of the immune system. 
They are capable of recognizing microbes and environmental substances and provide first line 
innate anti-viral immune defense. Moreover, they are capable of migrating to skin-draining 
lymph nodes, and of inducing T cell-mediated adaptive immune responses to antigens 
encountered in the epidermis. This unique epidermal dendritic cell (DC) subset is 
developmentally dependent on the cytokine TGF-β1 as evidenced from in vitro and in vivo data 
(Igyarto and Kaplan, 2012; Romani et al., 2012). 
 
TGF-β1 was identified as a factor inducing LC differentiation from human monocytopoietic cells 
in vitro (Strobl et al., 1996). While in the absence of TGF-β1, cytokine stimulated CD34+ 
hematopoietic progenitor cells (HPCs) developed into monocyte/macrophages, supplementation 
of these cultures with TGF-β1 directed progenitor cell differentiation towards LCs (Strobl et al., 
1997; Strobl et al., 1996). In line with this, neutralizing anti-TGF-β1 antibody abrogated LC 
differentiation (Caux et al., 1999) demonstrating that endogenous TGF-β1 in these cultures 
(Caux et al., 1992) is required for the induction of LC differentiation. Congruent with these 
observations, blood monocytes acquire LC characteristics in response to TGF-β1 stimulation 
(Geissmann et al., 1998; Hoshino et al., 2005). Murine in vivo data similarly demonstrated that 
LC differentiation depends on TGF-β1. LC networks are absent from TGF-β1-/- mice (Borkowski 
et al., 1996) and the specific deletion of TGF-β1 and TGF-βRII in LCs resulted in reduced 
numbers of epidermal LCs, indicating that TGF-β1 acts directly on LC differentiation (Kaplan et 
al., 2007). Congruent with these observations, LC networks were impaired in mice deficient for 
TGF-β1 downstream signaling molecules Id2 (Hacker et al., 2003) and Runx3 (Fainaru et al., 
2004). Together, these observations firmly established a key role of TGF-β1 during LC 
differentiation. 
 
Recent data however challenged the view that TGF-β1 is required for LC differentiation. First, 
LCs possess substantial proliferative capacity in the steady state (Merad et al., 2002) as well as 
during prenatal life or during inflammation (Chang-Rodriguez et al., 2005; Chorro et al., 2009; 
Schuster et al., 2009). These findings seem to be incompatible with the well-defined anti-
proliferative function of TGF-β1 (Dennler et al., 2002). Second, basal keratinocyte layers are 
devoid of TGF-β1 expression, which has been considered critical for keratinocyte stem cell 
proliferation (Li et al., 2006). Some LCs reside in basal keratinocyte layers and Ki67 staining 
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revealed that a fraction of these cells undergo proliferation in the steady-state adult skin 
(Schuster et al., 2009). Third, LC precursor seeding of the prenatal epidermis precedes TGF-β1 
expression induction in the epidermis. (Schuster et al., 2009). Fourth, the deletion of components 
of the canonical TGF-β1 signaling cascade still allowed normal LC differentiation in vivo. 
Canonical TGF-β1 signaling is transmitted via the type-I receptor ALK5 and also depends on 
type-II receptors, leading to the downstream activation of transcription factors Smad2/3 
(Massague, 1998). Deficiency of Smad3 failed to impair LC networks (Ying-Ping Xu, 2012). 
Similarly, the deletion of ALK5 from CD11c+ or CD207+ cells allowed LC differentiation as 
revealed from the presence of LC networks at birth; only postnatally LC numbers rapidly 
dropped due to the emigration of LCs from the epidermis to lymph nodes shortly after birth (Kel 
et al., 2010; Zahner et al., 2011). Consistently, the conditional deletion of TGF-β1 and TGF-βRII 
in LCs resulted in their migration to the lymph nodes likely due to enhanced pro-inflammatory 
cytokine production and LC activation (Bobr et al., 2012). TGF-β1 also interferes with the 
maturation and pro-inflammatory cytokine production by monocyte-derived DCs (Geissmann et 
al., 1999). Taken together, canonical TGF-β1-ALK5-Smad3 signaling seems to be critical for 
postnatal LC network maintenance but does not seem to be required for LC differentiation.  
 
While ALK5 is regarded as the classical TGF-β1 receptor, TGF-β1 can also activate other type-I 
receptors such as ALK1 (Goumans et al., 2002; Oh et al., 2000), ALK2 and ALK3 (Daly et al., 
2008; Ebner et al., 1993). ALK receptors form hetero- and homo-oligomers that are differentially 
activated by members of the TGF-β/BMP superfamily (Miyazono et al., 2010). Considering the 
above mentioned recent observations that TGF-β1 might not be critical for LC differentiation, 
we considered deciphering the mechanism underlying LC differentiation to be of major 
importance. We here identified BMP7 as a key factor inducing LC differentiation. 
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RESULTS  
 
TGF-β1 promotes LC differentiation through the type-I receptor ALK3. 
TGF-β1 is the classical ligand for ALK5 while ALK2 and ALK3 receptors are activated by both 
TGF-β1 (Daly et al., 2008) and bone morphogenetic proteins (BMPs) (Miyazono et al., 2010). 
We aimed to explore the downstream signaling mechanism governing TGF-β1-dependent LC 
differentiation. Hence, we added or not inhibitors of ALK4/5/7 (SB421543) or ALK2/3/6 
(dorsomorphin) to LC generation cultures. CD34+ cells were pretreated for 1 hour with either 
compound and were subsequently induced to differentiate into LCs in the presence of GM-CSF, 
SCF, TNF, FLT3L and TGF-β1. Without inhibitors, a fraction of day 3 generated cells readily 
exhibited LC phenotypic characteristics (CD1a+CD207+). Unexpectedly, ALK5 inhibition led to 
the generation of increased percentages of LCs, indicating that the canonical TGF-β1/ALK5 
downstream signaling is not only dispensable for LC generation but even negatively affects it 
(Figure 1A, left panel). In sharp contrast, interference with ALK2/3/6 receptor signaling strongly 
impaired LC generation, as evidenced by a substantial drop in percentages of LCs (Figure 1A, 
right panel). Consistently, the total numbers of day 7-generated LCs were higher in the presence 
of the ALK5 inhibitor in all three experiments analyzed (Figure 1B). In comparison, day 7 
cultures in the presence of ALK2/3 inhibitor did not contain any viable cells (data not shown), 
indicating that ALK2/3 signaling rather than ALK5 is critical for TGF-β1-dependent LC 
differentiation from progenitor cells.  
 To confirm these data, we transduced CD34+ cells with retroviral vectors encoding 
ALK2-, ALK3-, ALK5-IRES-GFP or empty control vector. Subsequently, we generated LCs 
from CD34+ cells as previously reported (Strobl et al., 1997). GFP+ gated cells were analyzed for 
LC characteristics. ALK3-transduced cells contained significantly higher percentages of 
CD207+CD1a+ cells as compared with empty control vector transduced cells. Moreover, neither 
ectopic ALK2 nor ALK5 resulted in altered percentages of LCs (Figure 1C). Together with the 
observation that ALK3 is expressed in the epidermis (Botchkarev et al., 1999; Hwang et al., 
2001), our loss and gain of function experiments indicate that TGF-β1 utilizes ALK3 signaling 
for promoting LC differentiation.  
 LC generation cultures contained only very low percentages of cells expressing CD11b 
and/or CD14, that did not change significantly in response to addition of ALK inhibitors (Figure 
1A). Moreover, ectopic ALK3 expression failed to promote the generation of cells expressing 
CD14, CD11b or the early myeloid marker myeloperoxidase (MPO) in LC generation cultures 
(Figure 1D). Similarly, ectopic ALK3 neither modulated percentages of cells exhibiting a 
CD11b+CD1a+CD207- monocyte-derived DC (moDC) phenotype nor a CD14+CD11b+ 
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monocyte/macrophage phenotype generated in specific cytokine combinations (Figure 1D). 
Therefore, ALK3 specifically promoted the generation of CD1a+CD207+ LCs among the various 
cell subsets analyzed. 
 
BMP7 is detectable in the basal epidermal layer during human prenatal development. 
Among various ALK3 ligands, only BMP7 has a predominant expression pattern in basal 
keratinocyte layers (Takahashi and Ikeda, 1996). Moreover, only BMP7 is strongly expressed in 
fetal epidermis at day 17.5 p.c. (Helder et al., 1995), a time window when LC precursors first 
appear in the fetal murine epidermis (Chang-Rodriguez et al., 2005; Chorro et al., 2009; Elbe et 
al., 1989; Romani et al., 1986). However, human data on the distribution of BMP7 among 
keratinocyte layers during prenatal development were lacking. We previously identified 
proliferating LCs in basal layers of human epidermis (Schuster et al., 2009) and demonstrate 
here that BMP7 is detectable in the epidermis from the earliest time point analyzed (8-10 weeks 
EGA, Figure 2A). Stratified epidermis at subsequent time points (11-14 weeks EGA, adult) 
contains BMP7 exclusively in basal/suprabasal layers (Figure 2A). In comparison, TGF-β1 
cannot be detected in the epidermis at 8 wk EGA (Figure 2B) (Schuster et al., 2009). Moreover 
TGF-β1 is undetectable in the basal epidermal layer and is only found suprabasally (Figure 2B) 
(Kane et al., 1990; Schuster et al., 2009). Therefore, we conclude that BMP7 expression 
precedes TGF-β1 expression during embryonic epidermal development and both molecules show 
an inverse expression pattern in the stratified epidermis: TGF-β1 exclusively suprabasally and 
BMP7 in the basal/germinative layer (Figure 2B). Given that epidermal LC precursors can be 
detected at 8-11 weeks EGA (Schuster et al., 2009) and reside in basal/suprabasal keratinocyte 
layers, these cells are primarily exposed to a BMP7+TGF-β1- microenvironment. Only LCs in 
suprabasal epidermal layers are also exposed to TGF-β1.  
 
Numeric and morphologic LC impairment in Bmp7 deficient mice. 
To study the potential role of BMP7 during LC differentiation in vivo, we analyzed Bmp7 
deficient mice (Zouvelou et al., 2009). These mice die shortly after birth limiting the analysis of 
the LC differentiation process. However, IA/ IE positive LCs can be already detected right after 
birth (P0) (Chorro et al., 2009). To assess the expression pattern of BMP7, epidermal sheets 
from Bmp7-LacZ mice were stained with X-gal. Widespread expression of BMP7 in murine 
keratinocytes was detected (Figure 3A) similar to human epidermal sections as shown in Figure 
2. Epidermal LC precursor cells acquire MHCII around birth (P0) with detectable 
langerin/CD207 expression appearing at P2 (Chorro et al., 2009). We therefore analyzed mice at 
P0 using antibodies against IA/IE (MHCII). Bmp7-deficient mice (P0) showed substantial 
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reductions in epidermal MHCII+ cell frequencies (Figure 3B). Interestingly, the MHCII+ cells in 
these mice exhibited lower numbers of dendritic processes compared to cells from wild type 
littermate controls (Figure 3C). 
 
BMP7-dependent activation of ALK3-Smad1/5/8 promotes LC differentiation. 
Considering the above described in vitro and in vivo observations, we hypothesized that BMP7 
might act as TGF-β1-independent positive regulator of LC differentiation and that the selective 
triggering of ALK3 by BMP7 might enable amplified LC generation. Hence we added BMP7 
instead of TGF-β1 to LC generation cultures and monitored percentages and total numbers of 
LCs. A hallmark characteristic of TGF-β1-induced in vitro generated LCs is the formation of 
huge macroscopically visible homotypic E-cadherin-mediated LC clusters (Figure 4A). 
Strikingly, BMP7 alone induces higher frequencies of LC clusters as well as on average higher 
percentages of E-cad+CD1a+CD207+ cells than TGF-β1 when added to these cultures (Figure 
4A). Accordingly, total numbers of CD1a+E-cad+CD207+ cells were significantly higher in 
BMP7 than in TGF-β1-supplemented cultures (Figure 4A). Therefore, BMP7 by far exceeds 
TGF-β1 in promoting LC generation. These observations are congruent with the above-described 
positive role of ALK3 in LC differentiation and with the observations that ALK5 (induced by 
TGF-β1 but not BMP7) inhibits LC generation. CFSE-labeling experiments confirmed superior 
proliferation of cells from BMP7-supplemented cultures relative to TGF-β1-treated cells (Figure 
4B-C).  
 In subsequent experiments we performed a side-by-side comparison of BMP7 with other 
BMPs known to be expressed in the adult epidermis (i.e. BMP2, BMP4 and BMP6 (Botchkarev, 
2003). Dose response experiments revealed that only BMP4 replaced BMP7 in inducing LC 
differentiation. Conversely, neither BMP2 nor BMP6 induced LC generation (data not shown). 
Immunohistology revealed that BMP4 is not detectable in human prenatal epidermis (data not 
shown) consistent with the fact that BMP4 expression can not be detected in interfollicular 
epidermis (Bitgood and McMahon, 1995; Lyons et al., 1989). 
 In subsequent experiments, we treated LC precursors with either TGF-β1 or BMP7 and 
analyzed the phosphorylation of Smad proteins. TGF-β1 induces phosphorylation of Smad2/3 (a 
signature of TGF-β signaling via ALK5) and Smad1/5/8 (a signature of canonical BMP signaling 
via ALK2/3) (Feng and Derynck, 2005; Schmierer and Hill, 2007). Conversely, BMP7 resulted 
in Smad1/5/8 phosphorylation only (Izumi et al., 2006) (Figure 5A). We next determined the 
expression levels of ALK 2, 3 and 5 receptors in TGF-β1-LCs or BMP7-LCs by qRT-PCR 
analysis during LC differentiation. TGF-β1-generated LCs exhibit higher expression levels of 
ALK5 than ALK3. Conversely, an inverse expression pattern was observed for BMP7-generated 
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LCs (ALK3>ALK5) (Figure 5B). TGF-β1 is known to be auto-induced by canonical TGF-β1-
ALK5 signaling. Accordingly, TGF-β1 mRNA was induced in TGF-β1-supplemented LC 
generation cultures. Conversely, BMP7-supplemented LC generation cultures did not exhibit 
induction of TGF-β1 mRNA (Figure 5C). These observations are consistent with our finding that 
LC differentiation occurs independently of ALK5/Smad2/3 signaling. 
 
BMP7-generated LCs produce higher amounts of pro-inflammatory cytokines in response 
to microbial signals than TGF-β1-generated LCs.  
TGF-β1 inhibits pro-inflammatory cytokine production and DC maturation (Geissmann et al., 
1999). Accordingly, ALK5 deficiency in LCs resulted in their spontaneous egress from the 
postnatal epidermis and this effect was accompanied by LC activation/maturation (Kel et al., 
2010). We analyzed whether BMP7-ALK3-dependent LCs show enhanced cytokine production 
relative to TGF-β1-induced LCs. LCs generated in the presence of BMP7 or TGF-β1 form large 
clusters allowing enrichment of E-cad+CD1a+CD207+ LCs using 1g-sedimentation (Figure 6A) 
(Gatti et al., 2000). LCs generated under both conditions, showed similar upregulation of T cell 
co-stimulatory molecules CD86 and CD83 in response to TLR ligands peptidoglycan (PGN) and 
Pam3CSK4 (Figure 6B). However, PGN-treated BMP7 LCs produced substantially higher 
amounts of proinflammatory cytokines (TNF, IL-1β, IL-6, IL-12p40 and IL-12p70) along with 
higher levels of immunosuppressive cytokine IL-10 compared with TGF-β1 LCs (Figure 6C). In 
the absence of TLR ligand, BMP7- or TGF-β1-generated LCs exhibited similar low expression 
levels of pro-inflammatory cytokines (Figure 6C). 
 Moreover, TLR-stimulated BMP7-generated LCs possessed higher allogeneic T cell 
immunostimulatory capacity than TGF-β1-generated LCs in 12 out of 14 independent 
experiments (Figure 6D). Additionally, these two LC populations differed in the induction of T 
helper (Th) responses from adult allogeneic T cells. Specifically, TGF-β1-LCs expressed high 
levels of the Th2-type chemokine thymus and activation-regulated chemokine (TARC)/CCL17 
than BMP7-LCs. Consistently, TGF-β1-LCs induced T cells producing higher amounts of IL-13 
and IL-5 (affiliated with Th2 responses); vice versa BMP7 LCs induced higher amounts of IFNγ 
(affiliated with Th1 responses) (Figure 6E and F). Lower cytokine production from cord blood T 
cells as compared to adult peripheral blood T cells (Figure 6F) is in line with previous 
observations (Gupta et al., 2005). 
 
Genome wide analysis shows similar gene expression by TGF-β1-LCs and BMP7-LCs. 
To rule out that the above-described differences in cytokine production and T cell stimulation of 
TGF-β1-LCs versus BMP7-LCs are due to differences in cell lineage identity, we performed 
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genome-wide cDNA microarray analyses of flow sorted CD1a+CD207+ cells. Both populations 
clustered together in terms of gene expression pattern observed in three independent experiments 
(Figure 7, donors A, B, C). Moreover, comparison with recently deposited data sets (Hutter et 
al., 2012; Lundberg et al., 2013) revealed a closer resemblance to ex vivo isolated human LCs 
(Hutter et al., 2012) than to CD34+ cell-derived LCs described in a recent study (Lundberg et al., 
2013). This latter study used a different cytokine combination to generate LCs (i.e. IL-4 instead 
of FLT3L) potentially explaining the observed differences. For example, it was previously 
reported that IL-4 antagonizes the induction of certain TGF-β1-induced LC marker 
characteristics when added to cultures of CD34+ progenitor cells containing GM-CSF and TNF 
(Caux et al., 1999).  
 
Late addition of TGF-β1 to BMP7 supplemented cultures enhances percentages of 
CD207+CD1a+ LCs. 
Whereas percentages of CD207+CD1a+ cells generated in the presence of TGF-β1 or BMP7 were 
equivalent, total cellularity was much higher in BMP7- than in TGF-β1-supplemented cultures 
(Figure 4A). We observed that BMP7-supplemented cultures contain markedly higher 
percentages of CD1a+E-cad+ cells that lacked CD207 (Figure 4A). Large percentages of these 
cells positively correlated with larger LC cluster numbers present in these cultures indicating that 
these cells may represent immediate precursors of LCs still capable of proliferation. Thus, we 
hypothesized that TGF-β1 might inhibit cell cycle progression, in turn allowing terminal LC 
differentiation, similarly as previously observed for erythropoiesis (Krystal et al., 1994). Hence, 
we analyzed whether CD1a+E-cad+CD207- cells from BMP7 LC generated cultures can be 
induced to differentiate into CD1a+E-cad+CD207+ cells by the late addition of TGF-β1. Adding 
TGF-β1 to BMP7 LC generation cultures at day 5 indeed resulted in higher percentages of 
CD1a+E-cad+CD207+ cells within 48 h and this effect was accompanied by diminished 
percentages of CD1a+E-cad+CD207- cells. Using this two-step culture system (BMP7, 5 days, 
followed by TGF-β1 for 48 h), very high numbers of CD1a+E-cad+CD207+ LCs were generated 
(Figure 8A). The first culture phase (BMP7-supplemented; no TGF-β1) can be prolonged from 5 
to 7 days (data not shown). Conversely, when TGF-β1 was added at day 0 to BMP7-
supplemented cultures, similar cellularity and percentages of LCs were observed as for TGF-β1 
alone (data not shown). Therefore, TGF-β1 effects dominate over BMP7 effects on cell 
proliferation in LC generation cultures. 
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BMP7 strongly promotes LC generation in serum-free medium devoid of TNFα and SCF. 
Given the strong effect of BMP7 on LC generation, we asked in subsequent experiments whether 
BMP7 signaling might allow elimination of other cytokine stimuli present in this culture model. 
Therefore, the above-mentioned two-step protocol was used for cytokine omission experiments. 
Specifically, we analyzed consequences of omission of individual or combinations of cytokines 
from the first culture phase. The omission of FLT3L led to substantially decreased percentages 
and numbers of LCs. Conversely, omission of both TNF and SCF - two factors that were 
previously shown to be critical for LC generation (Caux et al., 1992; Young et al., 1995) - did 
not affect LC generation (Figure 8B). Therefore, a cytokine combination containing BMP7, GM-
CSF and FLT3L, followed by TGF-β1 for the final 48 h efficiently induces the generation of 
CD207+CD1a+ LCs from progenitor cells. In conclusion, the addition of BMP7 allows the 
elimination of two critical cytokines from previously optimized LC generation protocols.  
 
TGF-β1 inhibits pro-inflammatory cytokine production by BMP7-generated LCs.  
While TGF-β1 generated LCs produce much lower levels of pro-inflammatory cytokines than 
BMP7 generated LCs in response to microbial stimuli (Figure 6C), LCs generated by using the 
sequential protocol (6 days BMP7, followed by 48 h TGF-β1) equaled LCs from TGF-β1 
supplemented LC generation cultures (Figure 8C). Therefore, TGF-β1 strongly impairs pro-
inflammatory cytokine production from BMP7-generated LCs. 
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DISCUSSION  
 
LCs reside within basal and suprabasal epidermal layers in adult human skin. During prenatal 
development, already the single layered epidermis is populated by LC precursors and undergoes 
considerable proliferation to allow a tight LC network formation before birth. Also in adult 
epidermal basal layers, a small portion of LCs proliferates as evidenced by the expression of 
Ki67 (Schuster et al., 2009). We here showed that LCs entering the epidermis are initially 
exposed to a BMP-7hi environment. BMP7 is strongly expressed in embryonic epidermis at 8 
weeks EGA, a time point when LC precursors are first detectable in human embryonic skin. In 
stratified epidermis in fetal and adult skin, BMP7 expression is restricted to basal and suprabasal 
keratinocyte layers, but is lost in outer epidermal layers. Inversely, TGF-β1 is induced in 
suprabasal layers only and is upregulated in outer epidermal layers (Kane et al., 1990; Schuster 
et al., 2009). Therefore, TGF-β1 shows a reciprocal distribution versus BMP7 in the epidermis. 
Consistently, BMP7 expression (EGA week 8) precedes TGF-β1 induction (EGA week 11, 
restricted to outer keratinocyte layers) during fetal epidermal development.  
 We further demonstrated that BMP7 induces LC differentiation accompanied by massive 
cell proliferation in vitro. Conversely, TGF-β1 inhibited LC activation and proliferation 
dominantly when added to BMP7-dependent LC generation cultures. BMP7 activates ALK3 
(canonical BMP signaling) in the absence of ALK5 (canonical TGF-β1 signaling). On the 
contrary, TGF-β1 activates both cascades. We showed by gain and loss of function studies that 
ALK3 signaling promotes LC differentiation. Together, here presented data indicate that LC 
differentiation and proliferation is induced by BMP7-ALK3 in the absence of canonical TGF-β1-
ALK5 signaling. Instead, canonical TGF-β1-ALK5 signaling has an important role for the 
maintenance of LC networks after birth (Kel et al., 2010). We showed that the addition of TGF-
β1 to BMP7-generated LCs inhibits TLR-mediated LC activation. Since the epidermis is 
populated with commensal bacteria immediately after birth, TGF-β1 in suprabasal/outer 
epidermal layers might inhibit LC activation, which in turn may secure LC network 
maintenance.  
 TGF-β1 inhibits LC activation at least in part by inducing negative signaling proteins 
such as Axl (Bauer et al., 2012) which contribute to low pro-inflammatory cytokine production 
in LCs. In support for this model, in vitro BMP7 generated LCs lacked Axl (T. Bauer, 
unpublished observations). Moreover, basal keratinocyte layers and LCs located in basal layers 
lacked Axl, thus demonstrating that Axl possesses a similar epidermal expression distribution as 
observed for TGF-β1 (Bauer et al., 2012). Consistently, a portion of ex vivo isolated LCs lacked 
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Axl (Bauer et al., 2012). The finding that only a portion of murine LCs show activation of 
Smad2/3 proteins (Bobr et al., 2012) is in line with the here proposed model that TGF-β1 is 
constitutively active only in a subset of LCs.  
 Four members of the BMP family can be detected in the epidermis (BMP2, BMP4, 
BMP6, BMP7) (Botchkarev, 2003). Among them, only BMP7 is expressed at high levels in 
basal keratinocyte layers. Moreover we demonstrated here that BMP7 is strongly expressed in 
single-layered fetal epidermis at 8 weeks EGA, a time point when LC precursors are first 
detectable in the epidermis. Our study is to our knowledge the first to show that BMP7 
expression is detectable in basal/suprabasal epidermal layers during human prenatal 
development. In comparison, BMP6 is absent or only very weakly expressed in basal 
keratinocyte layers and its expression correlates positively with increased keratinocyte 
differentiation (Lyons et al., 1989), similarly as shown for TGF-β1 (Bascom et al., 1989; Keski-
Oja and Koli, 1992). It was previously noted that BMP7 and BMP6 exhibit opposite expression 
distribution among murine epidermal keratinocyte layers (Lyons et al., 1989; Takahashi and 
Ikeda, 1996). The other BMPs i.e. BMP2 and BMP4 are predominantly expressed in the hair 
follicle epithelium and mesenchyme, but not or only weakly in interfollicular epidermis (Bitgood 
and McMahon, 1995; Lyons et al., 1989).  
 Bmp7 KO mice exhibited substantially reduced numbers of LCs with the remaining LCs 
being morphologically less “dendritic” as compared to LCs from wild type littermates. Therefore 
we here described non-redundant positive effects of BMP7 on LC differentiation in vivo. Our 
data however do not rule out that other BMPs/type-1 receptor agonists may exert (partial) 
redundancy with BMP7 in promoting LC differentiation. The observations that epidermal 
transgenic expression of the BMP/activin inhibitor follistatin reduces LC numbers (Stoitzner et 
al., 2005) are consistent with a major role of the BMP-ALK3-Smad1/5/8 pathway in LC 
differentiation in vivo.  
 Our mechanistic insights into LC differentiation allowed us to design a greatly improved 
protocol for LC generation from CD34+ hematopoietic progenitor cells in serum-free medium. 
Side-by-side analysis revealed that BMP7-supplemented cultures by far exceed TGF-β1-
supplemented cultures in terms of absolute numbers of generated LCs as revealed from LC 
cluster formation and immuno-phenotypic analyses. Therefore BMP7 signaling is sufficient to 
induce LCs. Additionally, BMP7 allowed to eliminate two other cytokines (i.e. SCF and TNF) 
from optimized LC generation cultures. Thus, a combination of only three cytokines, i.e. GM-
CSF, FLT3L and BMP7 with the late addition of TGF-β1 for 48 h was found optimal for 
generating high yields of LCs. We showed that TGF-β1 induces LC generation via ALK3. 
However, the co-activation of ALK5 led to a reduction of LC generation. As a net effect, this led 
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to only limited amounts of LC generation in previously optimized TGF-β1-dependent 
differentiation cultures of CD34+ cells. A key finding of our study was that the replacement of 
TGF-β1 by BMP7 allows circumventing ALK5-mediated proliferation inhibition observed by 
TGF-β1. Consequently, BMP7 allows the generation of high numbers of LCs. Nevertheless, the 
late addition of TGF-β1 for the final 48 h was beneficial since it led to elevated percentages of 
generated LCs, potentially due to a negative effect of TGF-β1 on cell proliferation. Additionally, 
late TGF-β1 led to inhibition of TLR-mediated pro-inflammatory cytokine production by LCs. 
On the other hand, BMP7-generated LCs not exposed to TGF-β1 were highly potent inducers of 
T cell proliferation. This differential requirement might reflect in vivo niches and could help to 
explain differential T cell responses depending on the site of LC activation. In support of this 
concept, BMP7-LCs and TGF-β1-LCs differed in provoking Th1 versus Th2 responses in vitro. 
Moreover, this newly developed BMP7-dependent LC generation procedure with or without late 
TGF-β1 might be of interest for inducing strong anti-viral/anti-tumor T cell responses.  
 In conclusion, we here provide a mechanistic model for LC differentiation that utilizes 
two different family members of the TGF-β/BMP superfamily: BMP7 induces LC differentiation 
and proliferation whereas TGF-β1 secures low levels of cytokine production by differentiated 
LCs, a potential prerequisite for postnatal LC network maintenance and function. 
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MATERIALS AND METHODS 
 
Isolation of cells. 
Cord blood samples were collected during healthy full-term deliveries. Approval was obtained 
from the Medical University of Vienna institutional review board for these studies. Informed 
consent was provided in accordance with the Declaration of Helsinki. CD34+ cells were isolated 
as previously described (Taschner et al., 2007). 
 
Cytokines and Reagents. 
Human stem-cell factor (SCF), thrombopoietin (TPO), tumor necrosis factor alpha (TNF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), fms-related tyrosine kinase 3 
ligand (FLT3L, interleukin-4 (IL-4), interleukin-6 (IL-6) and bone morphogenetic proteins 
(BMP4 and BMP6) were purchased from PeproTech (London, United Kingdom); transforming 
growth factor beta 1 (TGF-β1) was purchased from R&D Systems (Wiesbaden, Germany). 
BMP7 and BMP2 were purchased from ImmunoTools (Friesoythe, Germany). ALK4/5/7 
inhibitor (SB431542) and ALK2/3/6 inhibitor (dorsomorphin dihydrochloride) were purchased 
from, Tocris biosciences (Bristol, UK).  
 
In vitro culture of CD34+ cord blood hematopoietic stem cells. 
CD34+ cells were cultured for 2-3 days under progenitor expansion conditions (FLT3L, SCF and 
TPO, each at 50 ng/ml) in serum-free medium (X-VIVO 15 medium, Bio Whittaker, 
Walkersville, MD) before subculturing with lineage specific cytokines. LC cultures were 
described before (Strobl et al., 1997). In brief, pre-expanded CD34+ cells (2 - 4×104/ml per well) 
were cultured in 24-well tissue culture plates in serum-free CellGro DC medium (CellGenix) 
supplemented with GM-CSF (100 ng/ml), SCF (20 ng/ml), FLT3L (50 ng/ml), TNF (2.5 ng/ml), 
and TGF-β1 (0.5 ng/ml) for 7 days. Cultures were supplemented with 2.5 mM GlutaMax 
(Gibco/Invitrogen) and 125 U/ml each penicillin/streptomycin. LC clusters were purified as 
previously described (Gatti et al., 2000). For moDC generation, pre-expanded CD34+ cells (2 - 
4×104/ml per well) were first cultured in 24-well plate in CellGro DC medium (CellGenix) 
supplemented with 10% FCS in the presence of GM-CSF (100 ng/ml), SCF (20 ng/ml), FLT3L 
(50 ng/ml) and TNF (2.5 ng/ml) for 4 days, followed by GM-CSF (100 ng/ml) and IL-4 (25 
ng/ml) for 3 days in RPMI+10% FCS medium (Jurkin et al., 2010). For monocyte/macrophage 
(Mφ) generation, pre-expanded CD34+ cells (2 - 4×104/ml per well) were cultured in 24-well 
plate in the presence of M-CSF (100 ng/ml), IL-6 (20 ng/ml), FLT3L (50 ng/ml) and SCF (100 
ng/ml) in RPMI+10% FCS medium (Heinz et al., 2006). 
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RNA isolation and qRT-PCR. 
RNA was isolated using RNeasy Mini kit (QIAGEN). 1 µg RNA was reverse transcribed using 
Transcriptor First Strand cDNA kit (Roche) and oligo (dT) primers. Quantitative qRT-PCR 
analysis was performed as previously described (Yasmin et al., 2013). SYBR Green and CFX96 
Real-Time PCR system (Bio-Rad) were used for quantitative real-time PCR. Cycling conditions 
for qRT-PCR were 3 min at 95°C, followed by 40 cycles of 30 sec at 95°C, 30 sec at 60°C, and 
30 sec at 72°C. Following qRT-PCR primers were used; ALK2_F, 5′-
TTGGAGACAGCACTTTAGCAG-3′; ALK2_R, 5′-GCGAGCCACTGTTCTTTGT-3′; 
ALK3_F, 5′-GAGTTGCTGCATTGCTGAC-3′; ALK3_R, 5′-GAGCCATGTAGCGTTTGGT-
3′; ALK5_F, 5′-AGGCCAAATATCCCAAACAG-3′; ALK5_R, 5′-
TAGCTGCTCCATTGGCATAC-3′; TGF-β1_F, 5′-GTACCTGAACCCGTGTTGCT-3′; TGF-
β1_R, 5′-GTATCGCCAGGAATTGTTGC-3′; HPRT_F, 5′-GACCAGTCAACAGGGGACAT-
3′; HPRT_R, 5′-AACACTTCGTGGGGTCCTTTTC-3′; TARC_F, 5′-
CCATTCCCCTTAGAAAGCTG-3′; TARC_R, 5′-CTCTCAAGGCTTTGCAGGTA-3′. Results 
were analyzed using the delta delta Ct method and presented as fold difference in mRNA level 
relative to HPRT. 
 
Retroviral vectors, transfection of packaging cell lines and gene transduction. 
ALK2-HASLwt-IRES-GFP, ALK3-HASLwt-IRES-GFP and ALK5-HASLwt-IRES-GFP were 
obtained by cutting ALK2-HASLwt-pCDNA3, ALK3-HASLwt-pCDNA3 and ALK5-HASLwt-
pCDNA3 (kind gift of Dr. Peter ten Dijke, LUMC, MCB Netherlands) with EcoRI and XhoI and 
inserting it into PBMN-IRES-GFP vector. Transfection of packaging cell line phoenix-GP as 
well as infection of target cells was done as previously described (Platzer et al., 2004). In brief, 
to produce recombinant amphotropic retrovirus, vectors were transiently transfected into the 
packaging cell line Phoenix-GP (Gag-Pol) using a calcium-phosphate protocol 
(https://www.stanford.edu/group/nolan/protocols/pro_helper_dep.html). Phoenix-GP was co-
transfected with an expression plasmid encoding gibbon ape leukemia virus (GALV) envelope 
(gift from D. B. Kohn, Los Angeles, CA). Before gene transduction, fresh or thawed CD34+ cells 
were stimulated overnight in X-VIVO 15 medium supplemented with the cytokines SCF (50 
ng/mL), FLT3L (50 ng/mL), and TPO (50 ng/mL). Afterward, 1 mL retroviral supernatant 
(harvested 36 - 48 hours after transfection of packaging cells) was added to 4 x 104 CD34+ HPCs 
in the presence of plate bound RetroNectin (Takara Bio, Shiga, Japan) using non-tissue culture-
treated 24-well plates (Cellstar; Greiner Bio-One GmbH, Kremsmuenster, Austria) following the 
instructions of the manufacturer. Infections were repeated 2 to 3 times at intervals of 12 to 24 
hours using fresh virus supernatants in the presence of cytokines SCF, FLT3L and TPO. Within 
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60 hours of the first transduction cycle, cells were harvested and re-cultured in LC, moDCs and 
monocyte/macrophage (Mφ) lineage-conditions. 
 
Immunofluorescence and Immunohistochemistry. 
Prenatal and adult skin specimens were embedded in optimum cutting tissue compound (Tissue-
Tek; Sakura), snap frozen in liquid nitrogen and stored at -80°C until further processing. 
Sections (6 μm) were cut, air dried, fixed in ice-cold acetone for 10 min, blocked with PBS 2% 
BSA for 1 hour at RT and stained with the primary unconjugated control rabbit isotype IgG 
(1:200; sc-3888; Santa Cruz Biotechnology) or antibodies specific for BMP4 (1:100; ab31165, 
abcam) or BMP7 (1:200; LS-B4567/39975; LifeSpan Biosciences) overnight at 4°C. The slides 
were washed with PBS and stained with the secondary goat anti-rabbit Alexa Fluor 546 
(Invitrogen) for 2 hours at RT. Alexa Fluor 488 anti-Laminin5 (D4B5; Millipore) was used to 
visualize the dermo-epidermal junction. Nuclei were stained with DAPI. Pictures were taken 
using a LSM700 microscope and Zen 2009 software (Carl Zeiss, Vienna, Austria). For 
immunohistochemistry, human tissue sections were then incubated with anti-LAP (27232; R&D 
Systems) and anti–TGF-β1 serum (Santa Cruz Biotechnology, Inc.) overnight at 4°C, followed 
by biotin-conjugated goat anti–rabbit IgG for 2 h at room temperature using the Elite rabbit IgG 
Vectastain kits. Biotinylated antibodies were detected with HRP streptavidin and staining was 
visualized with amino-ethyl-carbazole (AEC; Dako). Finally, sections were mounted with 
Aquatex (Merck) and examined using a microscope (Eclipse 80; Nikon). Mouse epidermal 
sheets were prepared as described previously (Bauer et al., 2012). Epidermis was fixed in 
acetone for 10 – 20 min, blocked with PBS containing 2% BSA for 1 hour at RT and stained 
with Ab specific for I-A/I-E (PE-conjugated; 1:400; Biolegend) overnight at 4°C. The slides 
were washed with PBS and stained with DAPI to visualize the nuclei. Images from 7 randomly 
chosen microscopic fields were acquired. LCs were enumerated and mean values were 
calculated per ear sheet. Pictures were taken using a microscope (Eclipse 80i; Nikon) and Lucia 
G software (Laboratory Imaging). 
 
RNA isolation, amplification and gene chip hybridization. 
Total RNA from 3 independent donors was isolated from sorted cells by using RNeasy Micro 
Kit (QIAGEN) according to the manufacturer recommendations. Quality control with the RNA 
6000 Pico LabChip Kit (Agilent, Cat.No. 5065-1513) on Agilent BioAnalyzer 2100 (Agilent, 
Foster City , CA ) showed a RIN 9.9 - 10. cRNA target synthesis, amplification, hybridization to 
the GeneChip Human Genome U133 Plus 2.0 Array and scanning were done according to the 
standard protocols recommended by the manufacturer (Affymetrix, Santa Clara, CA). In brief, 
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cDNA was generated from 50 ng total RNA using T7-oligo(dT) promoter primer (Affymetrix 
GeneChip GeneChip® 3’ IVT Express Kit, Cat.No. 901228). After a second strand cDNA 
synthesis, cDNA was converted to cRNA by an in vitro transcription reaction (Life 
Technologies). Thereafter, cRNA was purified and the yield was controlled with a 
spectrophotometer. Labelled cRNA was purified, quality controlled with Agilent 2100 
Bioanalyzer and denatured at 94°C before hybriidization of 12 µg of the purified sample. The 
samples were hybridized to the Human Genome U133 Plus 2.0 Array at 45°C for 16 h (60 rpm) 
in an hybridization oven. The arrays were then processed on the Affymetrix Genechip® fluidics 
station 450: protocol FS450_0001 for Cartridge Arrays. They were washed, stained with 
streptavidin-PE (Affymetrix GeneChip® HT hybridization, Wash and Stain Kit (Cat No. 
900720), washed again and scanned with a GeneArray Scanner (Affymetrix GCS3000).  
Raw and normalized microarray experiments have been submitted to the Gene 
Expression Omnibus (GEO; accession number GSE49085). Fluorescent intensity was analyzed 
using the GeneChip Operating Software (GCOS) 1.1 (Affymetrix) and scaled to a target value of 
100. Data uploaded into Expression Console EC1.2.1.20 (Affymetrix), normalized with the 
MAS5 algorithm and for log transformed data (Robust Multi-Array (RMA)) was used for the 
generation of CEL-files. The intensities below 200 were considered to be below positive 
expression and compared with signal intensities of previously published arrays (Lundberg et al., 
2013) (MAS5 normalized data; Table SI). Transcripts differentially expressed among all samples 
were identified using ANOVA analysis within multiple testing cut off (false discovery rate 
(FDR) is 5%, significance level is 0.05). Relationship between different cell populations was 
demonstrated by the minimal spanning tree analysis. Additionally, hierarchical clustering was 
performed using Cluster 3.0, based on complete linkage and Euclidean distance measure and 
heat maps of selected genes (listed in Table SI) were subsequently produced using Java 
Treeview 1.0.12. Fold change of transcripts => 1.5 was considered as up regulation and vice 
versa. Fold change of important transcripts was compared with different subsets of LCs as 
described in Table SII.  
 
Bmp7∆/∆ mice and LacZ staining of tissues. 
The generation of Bmp7∆/∆ mice has previously been described (Zouvelou et al., 2009). All 
mouse lines were backcrossed for more than 8 generations into the C57Bl6/J background. 
Tissues from heterozygous Bmp7lacZ (Bmp7wt/lacZ) mice (expressing β-galactosidase under the 
control of the Bmp7 promoter) were stained with X-gal to identify the location of Bmp7 
expression. Briefly, isolated epidermal tissue was fixed in 2% formaldehyde, 0.2% 
glutaraldehyde, 0.01% sodium deoxycholate, 0.02% Nonidet-P40 (NP40) in PBS for 5 min, 
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washed with 2 mM MgCl2 and stained at RT in the dark for several hours to overnight in X-gal 
staining solution, which contained 0.1 M phosphate pH 7.3, 2 mM MgCl2, 0.01% sodium 
deoxycholate, 0.02% NP40, 5 mM K3[Fe(CN)6], 5 mM K4[Fe(CN)6] supplemented with 1 mg X-
Gal (Promega)/ml. The samples were washed and refixed in 4% PFA and mounted with water-
based Mowiol 4-88 (Sigma) and documented using a Leica DM-E microscope equipped with a 
Leica DFC290 camera. Experimental results were obtained from at least three independent 
samples. Mice were maintained at the animal facilities of the University of Zurich. Animal 
experiments were approved by the local veterinary authorities (permit 98/2011, Veterinäramt 
Zürich) in compliance with Swiss federal law (TSchG, TSchV) and cantonal by-laws in full 
compliance with the European Guideline 86/609/EC. This authority approval also included 
ethical approval. 
 
Western blot analysis. 
Cells were directly lysed in 13 SDS-loading dye at 95 C for 5 min. For Western blot analysis, 
lysates of 1 - 2x105 cells per lane were loaded on 10 % SDS-polyacrylamide gels. Resolved 
proteins were transferred to a polyvinylene-difluoride membrane (Immobilon-P; Millipore, 
Billerica, MA) as previously described (Yasmin et al., 2013). Membranes were probed with 
antibodies against rabbit-pSmad1 (Ser463/465)/Smad5 (Ser463/465)/Smad8 (Ser426/428), 
rabbit-pSmad2 (Ser465/467) and rabbit-pSmad3 (Ser423/425) (Cell Signaling Technology), 
rabbit-Smad1/5/8 (N-18)-R: sc-6031-R and goat-Smad2/3 (E-20): sc-6033 (Santa Cruz) followed 
by horseradish peroxidase (HRP)-conjugated goat anti-rabbit, rabbit anti-goat (Pierce 
Biotechnology, Rockford, IL). Detection was performed with the chemiluminescent substrate 
SuperSignal WestPico or WestDura (Pierce Biotechnology). 
 
Flow cytometry. 
Flow cytometry staining and analysis were performed as described previously (Yasmin et al., 
2013). Murine monoclonal antibodies (mAbs) of the following specificities were used: FITC-
conjugated mAb specific for CD1a, phycoerythrin (PE)-conjugated mAb specific for CD207 
(Immunotech, Marseille, France), allophycocyanin-conjugated antibody for CD324, pacific blue 
conjugated CD1a and CD14 (APC-CY7) (BioLegend, San Diego, CA), CD11b (PE-CY7; BD 
Bioscience) and MPO-C2 (PE; ADG ANDER GRUB, Austria). All stainings were done with 
permeabilized cells. Flow cytometric analysis was performed using an LSRII instrument (BD) 
and FlowJo software (Tree Star). 
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T cell proliferation assays. 
T cell proliferation assay (MLR) was performed as described before (Stockl et al., 1999). 
Briefly, purified LC clusters were seeded (5x104 to 1x105/500ul) in 48-well plate and activated 
with PGN. Graded numbers of these stimulator cells were co-cultured with a constant number of 
5 x 104 to 1 x 105 highly purified (> 98 %) allogeneic T cells in RPMI medium containing 10 % 
FCS using round-bottom, 96-well tissue culture plates (Nalge Europe, Brussels, Belgium). 
Proliferation of T cells was monitored on day 5 of culture by adding [methyl-3H]TdR followed 
by measuring [methyl-3H]TdR incorporation 18 hours later. Incorporated radioactivity was 
measured using a 1450 microbeta plate reader (Wallac-Trilux Instrument; Life Science, Vienna, 
Austria). The basal proliferation rate of T cell control was 900 ± 200 cell counts. Supernatents 
were collected for cytokine measurement before adding [methyl-3H]TdR. Assays were 
performed in triplicates. 
 
Cytokine measurement. 
Purified LC clusters were seeded (5x104 to 1x105/500μl) in 48-well plate. Cells were activated 
with PGN and supernatants were collected 48 hours later as described previously (Jurkin et al., 
2010). Quantification of cytokines produced by LCs or LC:T cell co-cultures was performed 
using the Luminex system (Austin, TX).  
 
Statistical analysis. 
Statistical analysis was performed using the paired, 2-tailed Student t test or ANOVA; p-values 
of less than 0.05 were considered significant.  
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FIGURE LEGENDS 
 
Figure 1. TGF-β1 induces LC differentiation through type-I receptor ALK3. 
(A) Pre-expanded CD34+ cells were treated or not with ALK4/5/7 inhibitor (SB421543) or 
ALK2/3/6 inhibitor (dorsomorphin) for 1 h before TGF-β1 addition. FACS plots represent day 3-
generated LCs in the presence or absence of inhibitors analyzed for CD1a+CD207+ by flow 
cytometry. Data are representative of six independent experiments. Bar diagrams represent 
percentages and total numbers of cells expressing CD1a+CD207+, CD1a+, CD11b+ or CD14+ 
cells (± SEM, *P < 0.05, **P < 0.004). (B) Day 7-generated LCs were incubated in the presence 
or absence of SB421543 and analyzed for CD1a and D207 by flow cytometry. Data are 
representative of three independent experiments. Graph represents total numbers of 
CD1a+CD207+ cells. (C) CD34+ cells were transduced with retroviral vectors encoding ALK2-, 
ALK3- or ALK5- IRES-GFP and were cultured in the presence of TGF-β1. FACS plots 
represent day 7-generated GFP+ cells analyzed for CD1a and CD207. Data are representative of 
three independent experiments. Bar diagram represent percentages of CD1a+CD207+ cells (± 
SEM, *P < 0.05). (D) CD34+ cells were transduced with retroviral vector encoding ALK3-IRES-
GFP and cultured in LC, moDCs and monocyte/macrophages (Mφ) lineage-conditions. FACS 
plot represent day 7-generated GFP+ cells analyzed for CD1a, CD207, CD11b, CD14 and MPO. 
Bar diagrams represent percentages of CD1a+, CD207+, CD11b+, CD14+ and MPO+ cells. Data 
are representative of four independent experiments (± SEM, *P < 0.05). 
 
Figure 2. BMP7 expression is detectable in the basal epidermis during human prenatal 
development. 
(A) Skin sections (6 μm) from prenatal and adult human skin were analyzed for the expression of 
BMP7 (red) or control. Nuclei and the dermo-epidermal junction were visualized with Dapi 
(blue) and mAb directed against Laminin 5 (green) respectively. Data are representative of three 
donors for 8 – 10 weeks EGA, two donors for 11 – 14 weeks EGA and three donors for healthy 
adult skin. Bars 50 μm. (B) Immunofluorescence staining of BMP7 and HLA-DR at 8 wk EGA 
and adult human skin. Immunohistochemical staining was performed on cryostat sections. TGF-
β1 was visualized with AEC (red). Data are representative of two independent experiments. Bars 
50 μm.  
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Figure 3. LC impairment in Bmp7 deficient mice. 
(A) Tissues from heterozygous Bmp7lacZ (Bmp7wt/lacZ) mice (expressing β-galactosidase under 
the control of the Bmp7 promoter) were stained with X-gal to identify the location of Bmp7 
expression. The Transcriptional activity of Bmp7 is revealed by lacZ staining in the epidermis of 
BMP7-lacZ mice. One representative image from 3 different mice and experiments is shown. (B) 
I-A/I-E–positive cells from the epidermis of WT and Bmp7-KO mice at birth (postnatal day 0 
P0) were enumerated and shown in I-A/I-E+ cells/mm2. Graph shows the number of I-A/I-E+ 
cells with each connected white and black dot, represents mean data from one independent litter. 
Bars indicate the mean ± SEM, *P < 0.05. (C) Representative immunofluorescence staining of 
an epidermal sheet from a WT and a BMP7-KO mouse. LCs were visualized with Abs against I-
A/I-E (red) and nuclei were stained with DAPI (blue). Data are representative of four 
independent experiments.  Insets represent higher magnification of framed areas. Bar: 50μm. 
 
Figure 4. BMP7 induce LC differentiation.  
(A) CD34+ cells were incubated with GM-CSF, FLT3L, SCF and TNF in the presence of TGF-
β1, BMP7 or control and morphology was assessed. FACS plots represent day 7-generated cells 
analyzed for the expression of CD1a, CD207 and E-cadherin. Bar diagrams represent 
percentages and total numbers of phenotypically defined cells generated as indicated. Data are 
representative of three independent experiments (*P < 0.05, **P < 0.005). (B-C) Cells were 
labeled with CFSE at day 4. CD1a+ cells (left, data are representative of four independent 
experiments) and CD207+ cells (right, data are representative of three independent experiments) 
were analyzed at day 6 by flow cytometry.  
 
Figure 5. Activation of Smad1/5/8 drives LC differentiation. 
(A) Pre-expanded CD34+ cells were treated with TGF-β1 or BMP7 for the indicated times. 
Levels of immunoblot pSmad2/3, Smad2/3, pSmad1/5/8 and Smad1/5/8 were analyzed. Data are 
representative of five independent experiments. (B) LCs were generated in the presence of TGF-
β1 or BMP7 and expression of ALK2, 3 and 5 was assessed during LC differentiation by qRT-
PCR. Values were normalized to HPRT. Data are representative of three independent 
experiments (± SD, *P < 0.05). (C) TGF-β1 expression during LC differentiation was assessed 
by qRT-PCR. Data are representative of three independent experiments (± SD).  
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Figure 6. Higher pro-inflammatory cytokine production by BMP7-generated microbial 
stimulated LCs. 
(A) Expanded CD34+ cells were induced to differentiate into LCs in response to TGF-β1 or 
BMP7 stimulation as in 4A. LC clusters were purified using 1 g sedimentation, and CD1a and 
CD207 expression were analyzed by flow cytometry. Data are representative of four independent 
experiments. (B) Cluster purified LCs (TGF-β1 or BMP7) were activated or not with 
peptidoglycan (PGN) or Pam3CSK4 for 2 days and CD80 and CD86 expression was analyzed by 
flow cytometry. Data are representative of four independent experiments. (C) Cluster purified 
LCs (TGF-β1 or BMP7) were activated or not with peptidoglycan (PGN) for 2 days and 
supernatants were collected for cytokine measurement. Bar diagrams represent amounts of 
cytokines produced. Data are representative of four independent experiments (± SD, *P < 0.05, 
**P < 0.005). (D) T cells (1x105) were stimulated with indicated numbers of LCs. Proliferation 
of T cells was monitored on day 5 of culture by adding [methyl-3H]TdR followed by measuring 
[methyl-3H]TdR incorporation 18 h later. Error bars represent standard error mean of triplicate 
values. Data are representative of fourteen independent experiments (CB; cord blood, PB; 
peripheral blood). (E) TGF-β1- or BMP7-generated LCs were stimulated with PGN for 2 days 
and TARC expression was analyzed by qRT-PCR. Data are representative of four independent 
experiments (± SEM). (F) Allogeneic T cells were co-cultured with activated TGF-β1- or 
BMP7-LCs and production of IFNγ, IL-13 and IL-5 was measured by using the Luminex system 
(Austin, TX). Data are representative of four independent experiments (± SEM, CB; cord blood, 
PB; peripheral blood).  
 
Figure 7. Gene expression analysis.  
Clustering using complete linkage algorithm on differentially expressed transcripts, identified by 
ANOVA analysis within multiple testing cut off (false discovery rate (FDR) is 5%, significance 
level is 0.05), demonstrates relationship among in vitro and ex vivo LCs. Heat map visualizing 
gene expression profiles of differentially expressed genes (listed in Table SI) upon hierarchical 
clustering with complete linkage and euclidean measure. Colors represent high (red) and low 
(blue) normalized intensity. CD1a+CD207+ cells were generated from three independent donors 
(A, B, C) in response to TGF-β1 or BMP7 and were flow sorted prior to analysis. 
 
Figure 8. Sequential addition of TGF-β1 to the BMP7-supplemented cultures enhances LC 
generation with minimal cytokine combination. 
(A) CD34+ cells were induced to differentiate into LCs in response to TGF-β1 or BMP7 for 7 
days. Parallel cultures contained BMP7 for 5 days followed by TGF-β1 for the final 48 h 
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(BMP7+ TGF-β1, right). Control cultures did not contain any exogenous TGF-β1 or BMP7 
(left). All the cultures were supplemented with GM-CSF, TNF, SCF and FLT3L. FACS plots 
represent day 7-generated cells analyzed for the expression of CD1a and CD207. Bar diagrams 
represent total numbers of CD1a+CD207+ cells observed in four independent experiments (± SD, 
*P < 0.05, **P < 0.005, **P < 0.0005). (B) LCs were generated in the presence of BMP7 for 6 
days followed by late TGF-β1 addition (48 h). In the first culture phase (d 1 – d 6), different 
cytokine combinations were tested. FACS plots represent day 7-generated cells analyzed for the 
expression of CD1a and CD207. Bar diagrams represent mean total numbers of CD1a+CD207+ 
cells (± SEM) observed in three independent experiments. Graph represents different cytokine 
combinations used during LC differentiation as designated by a, b, c, d, e (statistically 
significant:  a vs b; a vs e; b vs e, *P < 0.05). (C) LCs were generated in the presence of TGF-β1 
for 7 days. Parallel cultures contained BMP7 for 5 days followed by late addition of TGF-β1 (48 
h; BMP7+TGF-β1). All the cultures were supplemented with GM-CSF, TNF, SCF and FLT3L. 
LCs were cluster purified and activated or not with PGN for 48 h. Supernatants were collected 
for cytokine measurement. Bar diagrams represent mean amounts of cytokines produced in four 
independent experiments. 
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SUPPLEMENTARY INFORMATION 
 
Table SI. Comparison of expression levels of important transcripts in LCs. 
Yasmin et al. (Lundberg et al., 2013) 
Probe Set ID Gene Symbol in vitro CD34-LCs 
(BMP7) 
in vitro CD34-LCs 
(TGF-β1) 
in vitro 
CD34-LCs 
ex vivo LCs 
204438_at CD206/MRC1 +++ - +++ - 
220428_at CD207/Langerin +++ +++ +++ +++ 
207277_at CD209/DC-SIGN - - ++ - 
203799_at CD302/DCL-1 +++ +++ ++ +++ 
206682_at CLEC10A +++ +++ +++ + 
211709_s_at CLEC11A ++ + + - 
221698_s_at CLEC7A/Dectin1 +++ +++ +++ +++ 
211734_s_at FCER1A +++ +++ + +++ 
204232_at FCER1G +++ +++ ++ +++ 
203561_at FCGR2A +++ + - + 
210889_s_at FCGR2B +++ ++ - ++ 
211395_x_at FCGR2C +++ ++ - ++ 
218831_s_at FCGRT +++ +++ + ++ 
37408_at MRC2 +++ +++ ++ - 
224983_at SCARB2 ++ ++ + + 
206995_x_at SCARF1 +++ +++ - + 
210176_at TLR1 +++ +++ + - 
204924_at TLR2 +++ + + - 
Interleukins and their receptors 
206295_at IL18 +++ +++ + + 
219323_s_at IL18BP - - - ++ 
39402_at IL1B +++ ++ ++ +++ 
212659_s_at IL1RN +++ ++ + - 
202859_x_at IL8 ++ - - + 
204912_at IL10RA +++ +++ +++ +++ 
209575_at IL10RB +++ +++ + - 
201887_at IL13RA1 +++ +++ +++ +++ 
229101_at IL17RA +++ ++ + - 
219255_x_at IL17RB - - + - 
202948_at IL1R1 +++ +++ +++ +++ 
205403_at IL1R2 +++ +++ +++ +++ 
205227_at IL1RAP +++ +++ +++ ++ 
242809_at IL1RL1 - - + - 
237493_at IL22RA2 +++ +++ + - 
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205926_at IL27RA ++ ++ + + 
203233_at IL4R +++ +++ + + 
205945_at IL6R +++ +++ ++ ++ 
212195_at IL6ST +++ +++ +++ +++ 
226218_at IL7R +++ +++ ++ + 
Signaling Molecules 
209906_at C3AR1 +++ ++ + - 
211287_x_at CSF2RA +++ ++ + - 
205159_at CSF2RB +++ +++ +++ +++ 
225661_at IFNAR1 ++ ++ + - 
211676_s_at IFNGR1 +++ +++ - + 
201642_at IFNGR2 +++ +++ ++ ++ 
201105_at LGALS1 +++ +++ +++ +++ 
208949_s_at LGALS3 +++ +++ +++ +++ 
208934_s_at LGALS8 ++ ++ + + 
206631_at PTGER2 - - + - 
204897_at PTGER4 +++ +++ +++ +++ 
224937_at PTGFRN +++ +++ + - 
1552807_a_at SIGLEC10 +++ +++ +++ +++ 
207113_s_at TNF +++ +++ - ++ 
209295_at TNFRSF10B +++ +++ ++ + 
227345_at TNFRSF10D + + + - 
207037_at TNFRSF11A + + + - 
209354_at TNFRSF14 ++ ++ + + 
207643_s_at TNFRSF1A +++ +++ + + 
203508_at TNFRSF1B +++ ++ - + 
210314_x_at TNFSF13 +++ +++ ++ + 
CD antigens 
205055_at CD103 +++ +++ ++ + 
226545_at CD109 +++ +++ ++ ++ 
207315_at CD226 - - + - 
216379_x_at CD24 - - ++ - 
1559583_at CD276 - - + - 
217078_s_at CD300A +++ + - + 
209555_s_at CD36 +++ ++ +++ - 
216424_at CD4 - - - +++ 
217523_at CD44 ++ ++ +++ +++ 
208783_s_at CD46 +++ +++ +++ +++ 
242974_at CD47 ++ ++ ++ +++ 
204118_at CD48 +++ +++ + - 
34210_at CD52 +++ +++ ++ +++ 
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203416_at CD53 +++ +++ +++ +++ 
1555950_a_at CD55 +++ +++ + +++ 
205173_x_at CD58 +++ +++ ++ +++ 
200985_s_at CD59 +++ +++ ++ ++ 
200663_at CD63 +++ +++ +++ +++ 
209795_at CD69 +++ ++ ++ +++ 
207332_s_at CD71 +++ +++ +++ +++ 
209619_at CD74 +++ +++ +++ +++ 
1555779_a_at CD79A - - ++ ++ 
230391_at CD84 +++ +++ + + 
233317_at CD9 - - ++ +++ 
202877_s_at CD93 - - ++ - 
Chemokines and receptors 
216714_at CCL13 - - ++ - 
207900_at CCL17 ++ + + - 
207861_at CCL22 +++ +++ +++ +++ 
204103_at CCL4 - - - ++ 
205099_s_at CCR1 - - +++ - 
206978_at CCR2 + - +++ - 
206991_s_at CCR5 ++ - + - 
206337_at CCR7 + + + - 
219161_s_at CKLF +++ +++ +++ +++ 
205898_at CX3CR1 +++ +++ - +++ 
223454_at CXCL16 ++ - + +++ 
211919_s_at CXCR4 +++ + +++ ++ 
Maturation/Presentation 
35150_at CD40 ++ ++ + + 
200675_at CD81 +++ +++ +++ ++ 
204440_at CD83 +++ +++ +++ +++ 
210895_s_at CD86 +++ +++ + +++ 
206749_at CD1B +++ +++ +++ + 
205987_at CD1C +++ +++ +++ +++ 
210325_at CD1A +++ +++ +++ +++ 
215784_at CD1E +++ +++ +++ +++ 
205569_at CD208/LAMP3 +++ +++ +++ +++ 
Adhesion 
208654_s_at CD164 +++ +++ ++ ++ 
206120_at CD33 +++ +++ + - 
205884_at CD49D ++ - ++ - 
202910_s_at CD97 +++ +++ - ++ 
202637_s_at ICAM1 +++ +++ + + 
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204949_at ICAM3 +++ +++ +++ +++ 
209879_at SELPLG +++ +++ + + 
216537_s_at SIGLEC7 - - + - 
Others 
224629_at LMAN1 +++ +++ +++ ++ 
200805_at LMAN2 +++ +++ ++ + 
200900_s_at M6PR +++ +++ +++ ++ 
 
--Expression levels of transcripts encoding TLRs, CD antigens, lectins, TNF molecules, chemokines, 
interleukins and receptors, selected based on positive expression in the in vitro LCs.  
--Signal intensity levels (MAS5 based): - :< 200; + : 200-500; ++ : 500-1000; +++ :>1000.  
--LC - Langerhans Cell; CD34-LC - in vitro derived Langerhans Cell from CD34+ precursor. 
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Table SII. Comparison of fold change of important transcripts in LCs. 
Probe Set ID Gene 
Symbol 
in vitro 
CD34-LCs 
(BMP7) vs 
CD34-LCs 
(TGF-β1) 
in vitro 
CD34-LCs 
(BMP7) vs 
CD34-LCs  
(Lundberg et 
al., 2013) 
in vitro CD34-
LCs (TGF-β1) 
vs CD34-LCs  
(Lundberg et 
al., 2013) 
in vitro 
CD34-LCs 
(BMP7) vs ex 
vivo LCs 
(Hutter et al., 
2012) 
in vitro 
CD34-LCs 
(TGF-β1) vs 
ex vivo LCs 
(Hutter et 
al., 2012) 
ex vivo LCs 
(Hutter et 
al., 2012) vs 
CD34-LCs 
(Lundberg 
et al., 2013) 
Transcription Factors  
201566_x_at ID2 1.01 -2.62 -2.60 1.07 1.08 -2.81 
204198_s_at RUNX3 -1.28 3.41 4.36 6.45 8.23 -1.89 
204254_s_at VDR 1.15 1.06 -1.08 -2.52 -2.89 2.67 
1554411_at CTNNB1 1.29 5.77 4.47 7.54 5.85 -1.31 
202287_s_at TACSTD2 -1.09 -1.66 -1.52 1.11 1.21 -1.84 
201839_s_at EPCAM -1.34 -4.15 -3.09 1.43 1.92 -5.95 
204562_at IRF4 1.71 1.67 -1.02 -2.26 -3.85 3.77 
204057_at IRF8 1.26 -2.59 -3.27 2.95 2.34 -7.65 
228837_at TCF4 1.33 3.29 2.48 2.91 2.19 1.13 
228964_at PRDM1 1.35 -3.11 -4.20 -4.84 -6.52 1.55 
212611_at DTX4 1.07 1.21 1.13 1.45 1.36 -1.20 
221841_s_at KLF4 1.62 -15.45 -24.99 -3.56 -5.76 -4.34 
232231_at RUNX2 2.52 2.56 1.01 -9.79 -24.86 25.02 
203603_s_at ZEB2 1.66 5.41 3.26 -2.03 -3.37 10.98 
232739_at SPIB 1.19 1.08 -1.10 1.29 1.08 -1.20 
209710_at GATA2 1.50 1.73 1.16 -14.46 -21.67 25.08 
Interleukins and their receptors  
202859_x_at IL8 3.84 -23.19 -89.06 -23.17 -88.99 -1.00 
215719_x_at FAS 1.91 4.98 2.62 3.32 1.74 1.50 
205067_at IL1B 2.43 -1.14 -2.78 1.05 -2.31 -1.20 
205403_at IL1R2 2.69 -1.23 -3.31 -1.72 -4.64 1.40 
209828_s_at IL16 1.67 1.96 1.17 -1.86 -3.10 3.65 
229295_at IL17RA 2.23 8.33 3.73 -1.20 -2.69 10.04 
226218_at IL7R 2.28 34.30 15.06 2.48 1.09 13.84 
204912_at IL10RA 2.13 1.33 -1.61 -1.25 -2.67 1.66 
227125_at IFNAR2 1.47 1.35 -1.09 -4.28 -6.30 5.78 
222952_s_at TLR7 1.69 2.14 1.26 2.26 1.33 -1.05 
204924_at TLR2 2.91 6.70 2.30 -1.03 -3.00 6.90 
223750_s_at TLR10 1.41 4.48 3.17 4.02 2.84 1.12 
206337_at CCR7 1.99 1.59 -1.25 -2.35 -4.68 3.75 
Signaling Molecules and Receptors  
206943_at TGFBR1 1.20 1.65 1.98 1.85 2.22 -1.12 
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204832_s_at BMPR1A 1.00 -4.09 -4.09 -1.55 -1.55 -2.64 
213198_at ACVR1B 1.111 1.94 -1.87 -1.97 -2.05 3.83 
203935_at ACVR1 1.08 -1.56 -1.69 -1.09 -1.18 -1.43 
231873_at BMPR2 -1.15 4.92 5.86 5.52 6.36 -1.12 
210993_s_at SMAD1 1.17 4.26 3.64 -1.65 -1.94 7.04 
203075_at SMAD2 -1.05 -1.72 -1.64 -1.43 -1.36 -1.20 
205396_at SMAD3 1.13 -1.02 -1.15 -1.03 -1.16 1-01 
225219_at SMAD5 -1.10 2.07 2.29 1.19 1.32 1.74 
207069_s_at SMAD6 1.89 2.42 1.28 -1.63 -3.07 3.93 
1552398_a_at CLEC12A 1.47 1.94 1.33 -7.19 -10.54 13.97 
208450_at LGALS2 2.54 1.76 -1.45 1.47 -1.73 1.19 
1556209_at CLEC2B 1.50 -2.56 -3.83 1.32 -1.14 -3.36 
206682_at CLEC10A 2.44 6.61 2.71 -2.55 -6.21 16.83 
205884_at ITGA4 4.07 14.41 3.55 2.14 -1.90 6.74 
207345_at FST 1.27 1.04 -1.22 -1.72 -2.18 1.79 
204451_at FZD1 1.68 -4.23 -7.09 1.63 -1.03 -6.91 
238129_s_at FZD2 1.32 1.72 1.30 1.16 -1.5 1.49 
203705_s_at FZD7 1.77 1.02 -1.35 1.31 -1.74 1.29 
219890_at CLEC5A 2.61 -2.44 -6.36 1.92 -1.36 -4.68 
207085_x_at CSF2RA 1.85 7.98 4.31 5.40 2.92 1.48 
211286_x_at CSF2RA 1.50 5.39 3.60 2.91 1.94 1.85 
219761_at CLEC1A 1.32 -5.55 -7.76 -5.89 -7.31 -1.06 
233500_x_at CLEC2D 1.31 1.77 1.35 2.30 1.76 -1.30 
244413_at CLECL1 1.85 -1.03 -1.89 3.54 1.92 -3.64 
213475_s_at ITGAL 2.45 3.06 1.25 -1.36 -3.36 4.20 
227125_at IFNAR2 1.47 1.35 -1.09 -4.28 -6.30 5.78 
230619_at ARNT 1.23 1.77 1.44 -1.38 -1.70 2.44 
1554240_a_at ITGAL 3.32 4.26 1.28 -1.12 -3.73 4.79 
213416_at ITGA4 3.56 7.05 1.98 1.31 -2.73 5.40 
201656_at ITGA6 -2.99 -15.62 -5.22 -3.03 -1.01 -5.16 
CD antigens  
205153_s_at CD40 1.56 2.92 -1.05 1.29 2.16 2.26 
209555_s_at CD36 1.86 28.66 15.37 -7.26 -13.53 207.93 
204118_at CD48 1.71 8.34 4.88 1.15 -1.49 7.25 
201743_at CD14 2.08 3.78 1.82 3.18 1.53 1.19 
207176_s_at CD80 1.39 4.19 3.01 1.07 -1.30 3.90 
205685_at CD86 1.17 -2.25 -2.63 3.28 2.81 -7.39 
203547_at CD4 1.26 -2.61 -3.30 1.21 -1.05 -3.15 
211190_x_at CD84 1.05 -1.14 -1.19 1.01 -1.04 -1.15 
205987_at CD1c 3.70 -2.14 -7.93 -1.71 -6.33 -1.25 
210325_at CD1a -1.10 -1.53 1.39 -1.37 1.25 -1.12 
 36
Others  
211259_s_at BMP7 -1.03 -1.43 -1.40 -1.56 -1.52 1.09 
203084_at TGF-β1 1.07 -1.18 -1.25 1.37 1.23 -1.54 
205016_at TGFA 2.07 1.83 -1.13 -5.22 -10.84 9.58 
201130_s_at CDH1 -1.13 1.21 1.36 1.90 2.15 -1.57 
218182_s_at CLDN1 1.29 -3.82 -4.92 -1.97 -2.53 -1.94 
208712_at CCND1 2.78 -1.12 -3.12 -2.35 -6.53 2.09 
204959_at MNDA 4.26 -7.92 -33.73 -5.75 -24.47 -1.38 
1555745_a_at LYZ 2.82 46.23 16.39 -1.51 -4.25 69.72 
205569_at LAMP3 2.22 1.31 -1.69 -1.07 -2.37 1.40 
226498_at FLT1 2.25 -3.17 -7.14 -1.19 -2.67 -2.67 
206259_at PROC 2.46 3.10 1.26 -1.74 -4.28 5.41 
207808_s_at PROS1 1.55 -6.07 -9.40 -1.85 -2.86 -3.28 
205328_at CLDN10 1.33 1.06 -1.26 -2.00 -2.66 2.11 
200606_at DSP 1.97 -7.94 -15.67 28.83 14.60 -228.80 
202085_at TJP2 1.88 -5.06 -9.53 -3.98 -7.50 -1.27 
204122_at TYROBP 1.34 1.81 1.35 2.67 1.99 -1.48 
209716_at CSF1 1.15 -1.05 -1.21 -5.69 -6.52 5.40 
 
Up-regulated :> 1.5  
Down-regulated :< 1.5 
 
 
 
 








